Thioredoxin Systems
Thioredoxin Systems AB is a Swedish biomedical company dedicated to developing innovative antibiotics to combat antimicrobial resistance. Their flagship product, EbsArgent™, is a novel antibacterial treatment targeting resistant bacterial infections, especially urinary tract infections caused by multidrug-resistant bacteria. The company is committed to advancing medical solutions that address the global health threat of antibiotic resistance, leveraging groundbreaking redox biology research and a strong scientific legacy.
Industries
Nr. of Employees
small (1-50)
Thioredoxin Systems
Patents
Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith
US-11013730-B1
View DetailsComposition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US-10058542-B1
View Details
Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith
US-11013730-B1
View DetailsComposition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US-10058542-B1
View DetailsProducts
Combination antibiotic of a selenium-containing small molecule and silver ions for complicated urinary tract infections
A combination therapeutic composed of a small-molecule selenium compound together with low levels of silver ions, developed to irreversibly inhibit bacterial thioredoxin reductase and produce synergistic bactericidal activity against multidrug-resistant pathogens and biofilms; intended for treatment of complicated urinary tract infections.
Combination antibiotic of a selenium-containing small molecule and silver ions for complicated urinary tract infections
A combination therapeutic composed of a small-molecule selenium compound together with low levels of silver ions, developed to irreversibly inhibit bacterial thioredoxin reductase and produce synergistic bactericidal activity against multidrug-resistant pathogens and biofilms; intended for treatment of complicated urinary tract infections.
Expertise Areas
- Antibiotic drug discovery
- Redox biology and thioredoxin system research
- Preclinical in vivo infection models
- Microbiology and antimicrobial susceptibility testing
Key Technologies
- Small-molecule antimicrobial agents (selenium-containing compounds)
- Silver ion-based antimicrobial agents
- Targeting bacterial thioredoxin reductase
- Combination therapy formulation
News & Updates
Thioredoxin Systems AB announced the close of a SEK 25 million Series A financing round to support the development of EbsArgent™, a first-in-class antibiotic for urinary tract infections caused by antibiotic-resistant bacteria. The funding will support preclinical studies and Phase I clinical trials.
Thioredoxin Systems AB became a full member of BEAM Alliance, a community of European companies developing innovative products to tackle antimicrobial resistance.
The fundamental aspects of EbsArgent's antimicrobial technology have been awarded a granted patent by the European Patent Office.
The company welcomed Carlos Ratia Loncán as Laboratory Manager, a clinical microbiologist with a PhD from the University of Barcelona.
Thioredoxin Systems AB announced the close of a SEK 25 million Series A financing round to support the development of EbsArgent™, a first-in-class antibiotic for urinary tract infections caused by antibiotic-resistant bacteria. The funding will support preclinical studies and Phase I clinical trials.
Thioredoxin Systems AB became a full member of BEAM Alliance, a community of European companies developing innovative products to tackle antimicrobial resistance.
The fundamental aspects of EbsArgent's antimicrobial technology have been awarded a granted patent by the European Patent Office.
The company welcomed Carlos Ratia Loncán as Laboratory Manager, a clinical microbiologist with a PhD from the University of Barcelona.